Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of a safety and efficacy analysis

被引：0
|
作者：
Arkenau, HT
Schmoll, H
Kubicka, S
Kretzschmar, A
Freier, W
Seufferlein, T
Graeven, U
Grothey, A
Hinke, A
Porschen, R
机构：
[1] Clin Bremen E, Clin Internal Med, Bremen, Germany
[2] Univ Halle Wittenberg, Halle Saale, Germany
[3] Hannover Med Sch, D-3000 Hannover, Germany
[4] Charite, Berlin, Germany
[5] Private Oncol Clin, Hildesheim, Germany
[6] Univ Ulm, Med Clin, Ulm, Germany
[7] Hosp Maria Hilf, Monchengladbach, Germany
[8] Mayo Clin, Rochester, MN USA
[9] Res Inst WISP Langenfeld, Res Inst WISP, Langenfeld, Germany
[10] Clin Bremen E 10, Bremen, Germany
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：283 / 283
页数：1
相关论文
共 50 条
  • [21] Phase III study of 5-fluorouracil/leucovorin plus oxaliplatin versus capecitabine plus oxaliplatin as first line therapy in patients with advanced colorectal cancer (ACRC)
    Porschen, R
    Arkenau, T
    Kubicka, S
    Schmoll, HJ
    Seufferlein, T
    Graeven, U
    Grothey, A
    GASTROENTEROLOGY, 2005, 128 (04) : A438 - A438
  • [22] OXXEL (oxaliplatin plus Xeloda) versus oxafafu (oxaliplatin plus folinic acid-modulated 5-fluorouracil IV bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): Preliminary safety and activity analysis
    Sandomenico, C.
    Filippelli, G.
    Massidda, B.
    Putzu, C.
    Natale, D.
    Palmeri, S.
    Maiorino, L.
    Condemi, G.
    Leo, S.
    Gambardella, A.
    Comella, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI47 - XI47
  • [23] Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
    Arkenau, Hendrik-Tobias
    Arnold, Dirk
    Cassidy, Jim
    Diaz-Rubio, Eduardo
    Douillard, Jean-Yves
    Hochster, Howard
    Martoni, Andrea
    Grothey, Axel
    Hinke, Axel
    Schmiegel, Wolff
    Schmoll, Hans-Joachim
    Porschen, Rainer
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 5910 - 5917
  • [24] Protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first-line treatment in advanced colorectal cancer (ACRC): Preliminary results of the Italian phase IIFOCA study
    Martoni, Andrea
    Pinto, Carmine
    Di Fabio, Francesca
    Lelli, Giorgio
    Llimpe, Fabiola Lorena Rojas
    Gentile, Anna Lisa
    Mutri, Vita
    Ballardini, Pierluigi
    Giaquinta, Stefania
    Piana, Edera
    ANNALS OF ONCOLOGY, 2005, 16 : 47 - 47
  • [25] Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
    Kim, Han Jo
    Eun, Jun Young
    Jeon, Young Woo
    Yun, Jina
    Kim, Kyoung Ha
    Kim, Se Hyung
    Kim, Hyun Jung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Nam Su
    Lee, Kyu Taek
    Park, Seong-Kyu
    Won, Jong-Ho
    Hong, Dae Sik
    Park, Hee Sook
    CANCER RESEARCH AND TREATMENT, 2011, 43 (03): : 154 - 159
  • [26] 5-fluorouracil alone versus 5-fluorouracil plus folinic acid in the treatment of colorectal carcinoma: meta-analysis
    Lo Bello, L
    Pistone, G
    Restuccia, S
    Vinci, E
    Mazzoleni, G
    Malaguarnera, M
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2000, 38 (12) : 553 - 562
  • [27] Oxaliplatin, 5-fluorouracil, and folinic acid as first-line treatment in metastatic or recurrent gastric cancer
    Kim, H.
    Yun, J.
    Kim, K.
    Kim, S.
    Lee, S.
    Bae, S.
    Lee, K.
    Hong, D.
    Park, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Comparison of efficacy and safety of capecitabine and oxaliplatin (CAPOX) with epirubicin, oxaliplatin plus capecitabine (EOX) as first line treatment for advanced gastric cancer (AGC), a randomized clinical study
    Kayal, Smita
    Pani, Chinmaya Kumar
    Biswajit, Dubashi
    Verma, Surendrakumar
    Sistla, Sarath Chandra
    Cyriac, Sunu Lazar
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
    Tomas Buchler
    Tomas Pavlik
    Bohuslav Melichar
    Zbynek Bortlicek
    Zuzana Usiakova
    Ladislav Dusek
    Igor Kiss
    Milan Kohoutek
    Vera Benesova
    Rostislav Vyzula
    Jitka Abrahamova
    Radka Obermannova
    BMC Cancer, 14
  • [30] Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
    Buchler, Tomas
    Pavlik, Tomas
    Melichar, Bohuslav
    Bortlicek, Zbynek
    Usiakova, Zuzana
    Dusek, Ladislav
    Kiss, Igor
    Kohoutek, Milan
    Benesova, Vera
    Vyzula, Rostislav
    Abrahamova, Jitka
    Obermannova, Radka
    BMC CANCER, 2014, 14
12345